Interpreting blood biomarker test results in familial Alzheimer’s disease
A Youngtimers Guide ・ Last Reviewed Nov 12 2025
Rules that matter more than any single number
After years of research and data from FAD families, a few principles stand above all others when it comes to interpreting biomarker results.
Trends beat single numbers. One test result is a photograph. A series of results over years is a film. The film tells far more. A p-tau217 result that looks borderline today means something very different depending on whether it has been stable for three years or has been climbing steadily.
Convergence beats any one test. When two or three markers move in the same direction at the same time, that is a meaningful signal. When only one marker nudges slightly while others are stable, that is likely noise.
Acceleration matters more than thresholds. Crossing an "abnormal" cutoff on a single test is less important than whether markers are rising faster than before. Rate of change is the real story.
Testing more than annually rarely helps. In most phases, testing every few months does not add clarity. The biology moves over months and years, not weeks.
Knowledge should reduce uncertainty, not steal peace. This is perhaps the most important principle. If testing is causing more distress than clarity, that is worth raising with a care team. The purpose of this information is to empower, not to replace one kind of fear with another.
A simple default plan
For those unsure where to start, here is a reasonable framework to discuss with a doctor.
Amyloid-negative results: Test every two years
Amyloid borderline or positive: Test annually
Multiple markers rising together: Discuss with a doctor whether to shorten intervals or pursue additional evaluation, but not based on a single test alone
What biomarkers can and cannot tell us
Biomarkers will not give an exact age of symptom onset. That is beyond what current science can reliably deliver.
What they can tell us, with real confidence:
Pre-pathology: "Not soon." There is road ahead.
Silent pathology: "Still years away, but worth watching closely." Stay engaged with healthy lifestyle choices and Alzheimer’s research.
Transition phase: "Risk is rising". This is the time to lock in legal and financial planning, care planning, documented preferences, and the like.
Right now, that is the maximum resolution modern neurology can offer. Used wisely, it can help inform meaningful decisions.
Support is key.
With proper counseling, a knowledgeable care team, and the support of this community, your blood test results can be empowering.
Consider speaking with a genetic counselor or Alzheimer's specialist who understands FAD biology. A good counselor will help work through what the results might mean, how to interpret different outcomes, and how to make decisions that align with personal values and circumstances.
If it feels like a lot to take in, you are not alone. Connect with others who are navigating the same questions through our Support Groups or Peer-to-Peer Program.
And if you’re considering research participation, start with our guide to Participating in Research.